A Phase 1/2 interventional study of Lucitanib and Lucitanib in Advanced Solid Tumor and Gynecologic Cancer, sponsored by Clovis Oncology, Inc.. Suspended at 27 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-20.
Sponsored by Clovis Oncology, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Genital Neoplasms, Female with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Genital Neoplasms, Female · United States.
Among the 37 studies in Genital Neoplasms, Female with a site in United States, this one is the 7th largest by planned enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2019, is one of 3 in phase 1/2, and was the 23rd registered.
81 studies on the registry are indexed under Genital Neoplasms, Female; 18 are open to participants now.
Browse Genital Neoplasms, Female studies →6 of the 37 studies in Genital Neoplasms, Female with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+ · Women only
Corcept Therapeutics · Sites in United States, Belgium, France and 5 more countries
Ages 18+ · Women only
University of Utah · Sites in United States
Ages 18+ · Women only
University of California, San Francisco · Sites in United States
Ages 18+ · Women only
Marengo Therapeutics, Inc. · Sites in United States, Canada, France and 1 more country
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Genital Neoplasms, Female studies recruiting now, 8 (57%) set no upper age limit and 5 (36%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 10 · Phase 3 2
First in 1999; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 227 is above the median of 78 across 63 interventional studies indexed under Genital Neoplasms, Female.
Median enrollment 40 across the 33 interventional studies, 750 across the 4 observational. Of the 24 that completed or were terminated, 13 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 37 have an industry lead sponsor. The 10 most frequent:
Clovis Oncology, Inc. is the lead sponsor of 14 studies on the registry; none are open to participants now.
Clovis Oncology, Inc. has 1 study filed under Genital Neoplasms, Female — fewer than ten, so there is no comparison to draw.
6 of the studies in Genital Neoplasms, Female with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05979610University of UtahUsing Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies | 2026-12 |
| NCT06533059Alterome Therapeutics, Inc.A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | 2026-12-29 |
| NCT03141437M.D. Anderson Cancer CenterDecision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer | 2027-04-30 |
| NCT05592626Marengo Therapeutics, Inc.A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | 2027-09 |
| NCT05053230Memorial Sloan Kettering Cancer CenterA Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer | 2027-09-20 |
Add all 6 to your calendar (.ics) → With an account.
Among the 37 studies in Genital Neoplasms, Female with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, Phase 1b/2 study to determine the recommended dose of lucitanib in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of lucitanib and nivolumab in patients with an advanced gynecological solid tumor (Phase 2) and evaluate the effects of dosing under fasting or fed state (Food Effect)
General Inclusion Criteria:
General Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
- Up to 50 patients with advanced solid tumor
Drug: Lucitanib · Drug: Nivolumab
- Approximately 16 evaluable patients with an advanced, metastatic solid tumor will be enrolled
Drug: Lucitanib · Drug: Nivolumab
* Recurrent endometrial carcinoma at least 1 prior platinum-based chemotherapy regimen * Up to 10 patients who have progressed on treatment with 1 prior PD-(L)1 inhibitor administered as monotherapy will be allowed to enroll
Drug: Lucitanib · Drug: Nivolumab
* Recurrent high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, of any histology excluding clear cell carcinoma * At least 2 prior chemotherapy regimens which at least 1 must have been platinum-doublet chemotherapy * Up to 10 subjects with recurrent ovarian, fallopian tube, or primary peritoneal cancer, of any histology excluding clear cell carcinoma who have progressed within 6 months after completing first-line platinum-based chemotherapy will be allowed to enroll
Drug: Lucitanib · Drug: Nivolumab
* Recurrent, metastatic clear cell carcinoma of ovarian, fallopian tube, primary peritoneal or endometrial origin * At least 1 prior platinum- and taxane-based chemotherapy regimen
Drug: Lucitanib · Drug: Nivolumab
* Persistent or recurrent cervix cancer of squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma histology * At least 1 prior regimen of platinum-based chemotherapy, with or without bevacizumab, for metastatic disease
Drug: Lucitanib · Drug: Nivolumab
Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.
Also known as: CO-3810
Oral lucitanib will be administered once daily (QD). The dose will be 6 mg.
Also known as: CO-3810
Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg. Subjects will be allowed to intrapatient dose escalate in increments of 2 mg up to a total dose of 10 mg QD lucitanib if they meet the study specific clinical criteria.
Also known as: CO-3810
IV nivolumab 480 mg will be administered once every 4 weeks.
Also known as: Opdivo, BMS-936558
Determine the recommended Phase 2 dose of the combination of lucitanib and nivolumab (Phase 1b)
Incidence of adverse events and clinical lab abnormalities defined as dose-limiting toxicities and maximum tolerated dose.
Time frame: First dose of study drug through at least 100 days after end of treatment (up to approximately 2 years)
Best Overall Response Rate (Phase 2)
Confirmed best overall response (PR or CR) based on investigator assessment of objective response according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Time frame: From first dose of study drug until disease progression (up to approximately 2 years)
Acute and long-term safety and tolerability of the combination (Phase 2)
Incidence of AEs, clinical lab abnormalities, and dose modifications.
Time frame: From first dose of study drug until disease progression (up to approximately 2 years)
Further evaluation of preliminary efficacy of combination (Phase 2)
Duration of response, progression-free survival, and disease control per RECIST v1.1, overall survival.
Time frame: From first dose of study drug until at least 100 days after end of treatment (up to approximately 2 years)
Lucitanib PK Profile at Steady State [Phase 1 dose escalation and Food Effect]
Area under the curve \[AUCss\]
Time frame: From first dose of study drug to the end of Cycle 1 (each cycle is 28 days)
Lucitanib PK Profile at Steady State [Phase 1 dose escalation and Food Effect]
Maximum plasma concentration \[Cmax,ss\]
Time frame: From first dose of study drug to the end of Cycle 1 (each cycle is 28 days)
Lucitanib PK Profile at Steady State [Phase 1 dose escalation and Food Effect]
Total clearance of drug after oral administration \[CLss/F\]
Time frame: From first dose of study drug to the end of Cycle 1 (each cycle is 28 days)
Lucitanib PK Profile at Steady State [Phase 1 dose escalation and Food Effect, Phase 2]
Minimum plasma concentration \[Cmin,ss\]
Time frame: From Cycle 2 to Cycle 5 (each cycle is 28 days)
Lucitanib PK Profile at single dose [Food Effect Cohort]
Area under the curve \[AUC\]
Time frame: From first dose of study drug to Day -1
Lucitanib PK Profile at single dose [Food Effect Cohort]
Maximum plasma concentration \[Cmax\]
Time frame: From first dose of study drug to Day -1
Lucitanib PK Profile at single dose [Food Effect Cohort]
Time to maximum plasma concentration \[Tmax\]
Time frame: From first dose of study drug to Day -1
The effect of food (fasted or fed) on the Lucitanib PK Profile [Food Effect Cohort]
Area under the curve \[AUC\]
Time frame: From first dose of study drug to Day -1
The effect of food (fasted or fed) on the Lucitanib PK Profile [Food Effect Cohort]
Maximum plasma concentration \[Cmax\]
Time frame: From first dose of study drug to Day -1
The effect of food (fasted or fed) on the Lucitanib PK Profile [Food Effect Cohort]
Time to maximum plasma concentration \[Tmax\]
Time frame: From first dose of study drug to Day -1
Plan to share: Yes — De-identified datasets for study results will be made available to qualified researchers in compliance with applicable privacy laws and data protection regulations. Data will be provided by Clovis Oncology.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be made available to qualified researchers after the primary, secondary, and/or exploratory outcomes of the study are reported or published and for 1 year thereafter.
Access criteria: Requests for de-identified datasets will be made available to qualified researchers following submission of a methodologically sound proposal to medinfo@clovisoncology.com.
No publications or documents are linked to this record.
Started Jul 2019 (actual). Primary completion is estimated for Jul 2023, 48 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is suspended, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: E-3810
Clovis Oncology, Inc.